• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

MedAlliance wins second FDA IDE nod for drug-coated balloon

August 9, 2022 By Sean Whooley

MedAlliance SELUTION SLRMedAlliance announced today that received conditional FDA investigational device exemption (IDE) for its Selution SLR system.

The FDA IDE nod for the novel sirolimus-eluting balloon allows MedAlliance to initiate a pivotal clinical trial for use of Selution SLR in the treatment of occlusive disease of the superficial femoral artery (SFA).

Geneva, Switzerland-based MedAlliance’s second IDE nod follows the same approval for use of Selution SLR in treating BTK (below-the-knee) indications in May. MedAlliance began enrolling in that trial in June.

Enrollment for the Selution SLR IDE SFA study will begin later this year, according to a news release. The study will be conducted over 20 centers in the U.S. and at an additional 20 centers around the globe.

“This is a significant milestone for MedAlliance: we are the first non-paclitaxel drug-coated balloon to receive IDE approval, and now the first to have two applications approved.  This is the culmination of a multi-year R&D program to provide the comprehensive non-clinical data required to satisfy the very high standards expected by the U.S. FDA,” MedAlliance Chair and CEO Jeffrey B. Jump said in the release. “We are very pleased with the rapid level of sales growth we are experiencing in Europe, Asia and South America and very much look forward to entering the U.S. market”.

The company intends to enroll 300 patients to demonstrate superiority over balloon angioplasty (POBA).  The Principal Investigator of this study is Dr. George Adams, director of cardiovascular and peripheral vascular research at Rex Hospital Inc., Raleigh, North Carolina.

“We are very excited that US patients suffering from PAD will have the opportunity to receive this novel sirolimus drug-coated balloon technology,” said Adams. “This is yet another advancement in the field of treating vascular disease and we are confident that this study will enroll quickly.”

Selution SLR (sustained limus release) features unique micro-reservoirs made of biodegradable polymer intermixed with sirolimus. The micro-reservoirs provide a controlled and permanent release of the drug for up to 90 days, while MedAlliance’s CAT (cell-adherent technology) allows microdeposits to coat the balloons and adhere to the vessel lumen when delivered through an angioplasty balloon.

The platform was granted CE mark approval for treating peripheral artery disease in February 2020, then for treating coronary artery disease in May 2020. FDA has granted Selution SLR four breakthrough nods: for the treatment of atherosclerotic lesions in native coronary arteries; coronary in-stent restenosis; peripheral below-the-knee and AV-fistula indications.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Vascular Tagged With: FDA, MedAlliance

IN CASE YOU MISSED IT

  • Dexcom updates CGM receiver recall that led to serious adverse events
  • Abbott reports momentum with Libre CGM business as new dual sensor will ‘accelerate’ growth
  • Johnson & Johnson wins FDA priority review for drug delivery system
  • Glucose monitoring company LifeScan files chapter 11 to reduce debt
  • Medtronic enrolls first patient in study for Onyx liquid embolic system

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS